TBC3486
TBC3486 is a highly selective integrin α4β1 inhibitor. TBC3486 acts as a chemosensitizer to enhance the sensitivity of leukemia cells to chemotherapy. TBC3486 exhibits efficacy in preclinical models of integrin α4-dependent inflammatory and autoimmune diseases, including a mouse model of autoimmune encephalomyelitis. TBC3486 can be used for the research of precursor B-cell acute lymphoblastic leukemia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 247044-77-5
- Formel: C27H31N3O6S2
- Molecular Weight:557.68
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
TBC3486 (5-25 μM; 4 days) dose-dependently reduces adhesion of pre-B-ALL LAX7R cells to OP9 stromal cells[1].
TBC3486 (25 μM; 4 days) specifically downregulates integrin α4 expression in pre-B-ALL LAX7R cells without altering integrin α5 or integrin α6 expression[1].
TBC3486 (25 μM; 2 days) significantly reduces adhesion of pre-B-ALL LAX7R, ICN3, and SFO3 cells to human VCAM-1, with the greatest effect observed in CD49d-high LAX7R cells[1].
TBC3486 (25 μM; 2 days) does not affect the viability of pre-B-ALL LAX7R, ICN3, or SFO3 cells[1].
TBC3486 (25 μM; 4 days, in combination with VDL chemotherapy) sensitizes pre-B-ALL LAX7R, ICN3, and SFO3 cells to Vincristine (HY-N0488A), Dexamethasone (HY-14648) and L-asparaginase (HY-P1923) chemotherapy, significantly reducing cell viability compared to chemotherapy alone[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Patient-derived pre-B-cell acute lymphoblastic leukemia (pre-B-ALL) LAX7R, ICN3, and SFO3 cells
-
Concentration:25 μM
-
Incubation Time:2 days
-
Result:Had no effect on the viability of LAX7R, ICN3, or SFO3 cells compared to control.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID (xenotolerant)[1]
-
Dosage:10 mg/kg/day
-
Administration:i.p.; two injections per day; daily for 2 weeks
-
Result:Extended median survival time to 41 days compared to control MST of 33 days.
Chemical Information
-
CAS. Nr. 247044-77-5
-
Molecular Weight 557.68
-
Formel C27H31N3O6S2
-
SMILES
[C@H](NC(N[C@H](C(N(CC1=CC=CS1)CC2=CC=CS2)=O)CCCC)=O)(CC(O)=O)C=3C=C4C(=CC3)OCO4
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
TBC3486 Related Classifications
HY-122023 Related Classifications
Powered by Bioz